|
Indian Pediatr 2014;51: 295-297 |
|
Prevalence and Risk Factors for Allergic
Bronchopulmonary Aspergillosis in Indian Children with Cystic
Fibrosis
|
VK Sharma, D Raj, *I Xess, R Lodha and SK Kabra
From Department of Pediatrics and * Microbiology, All
India Institute of Medical Sciences, New Delhi, India.
Correspondence to: Dr Varun K Sharma, Senior
Resident, Department of Pediatrics, All India Institute of Medical
Sciences, New Delhi 110 029, India.
Email: [email protected]
Received: June 15, 2013,
Initial review: July 09, 2013;
Accepted: January 22, 2014.
|
Objectives: Allergic
bronchopulmonary aspergillosis (ABPA) is a common complication in
patients with cystic fibrosis. This cross-sectional study was planned to
determine the prevalence and risk factors for ABPA in Indian children
with cystic fibrosis.
Methods: Clinical evaluation,
spirometry, chest radiograph, sputum, total IgE, specific IgE for
Aspergillus fumigatus, IgG precipitins and skin prick tests were done in
33 CF patients.
Results: Prevalence of allergic
bronchopulmonary aspergillosis was 18.2% (95% CI 6.9% - 35.4%): allergic
bronchopulmonary aspergillosis was higher in patients with low cystic
fibrosis score, age >12 years, atopy, and eosinophilia.
Conclusion: Prevalence of ABPA is
higher in Indian children with cystic fibrosis.
Keywords: Aspergillus, Bronchiectasis,
Epidemiology.
|
Aspergillus colonization increases with age in
children with cystic fibrosis [1]. Prevalence of allergic
bronchopulmonary aspergillosis (ABPA) ranges from 2% to 15%. Older age,
poor nutritional status, atopy, use of inhaled antibiotics, inhaled
corticosteroid, long-term azithromycin therapy, RhDNase therapy, and
Pseudomonas infection are some risk factors [2]. Cystic fibrosis is
increasingly being diagnosed in Indian sub-continent and there is
paucity of data from the region.
Methods
This cross-sectional study was conducted in Pediatric
chest clinic of All India Institute of Medical Sciences, New Delhi,
India. The study was approved by the Institutional ethics committee.
Informed written consent was taken. Clinical evaluation, spirometry,
chest radiograph, sputum, total IgE, specific IgE for Aspergillus
fumigatus, IgG precipitins and skin prick test (SPT) were done.
ImmunoCAP test was used for estimation of total IgE, A. fumigatus
specific IgE and common aeroallergen [3]. IgG precipitins were assayed
by agar gel double diffusion method [4]. SPT was done using A.
fumigatus extracts (All Cure Pharma Pvt. Ltd. Bahadurgarh, Haryana)
[5].
We assessed the following risk factors: age, gender,
body mass index (BMI), CF score, atopy, airway reversibility, inhaled or
systemic antibiotics, inhaled corticosteroid (ICS), azithromycin,
Pseudomonas and aspergillus colonization. CF score was estimated
using Shwachman-Kulczycki score [6]. The diagnosis of ABPA was based on
the criteria suggested by the Cystic Fibrosis Foundation [7].
Aspergillus colonization was defined as the presence of Aspergillus
species in sputum from two samples collected on two consecutive days
[8]. Aspergillus sensitization was defined as positive specific IgE
(>3.5 KU) in serum against A. fumigatus or immediate cutaneous
reactivity [7]. Eosinophilia was defined as absolute eosinophil count
(AEC) > 500/mm 3.
Atopy was defined as >1 IU/mL IgE antibody to more than one aeroallergen
[9]. Analyses were done using Stata 9.0 software (Stata Corp., College
Station, TX, USA). Continuous and categorical variables were analyzed by
Student-t-test and Odds ratio (95% CI), respectively.
Results
Out of 41 children with CF, 33 (24 boys) were
enrolled. The mean (SD) age was 141.5 (58.5) months. The mean (range)
age at diagnosis of CF was 46.2 (2-138) months. The mean (SD) BMI was
14.38 (2.41) kg/m 2.
Chest radiographs were abnormal in 26 (78.7%) patients, with
bronchiectasis seen in 15 (45%).
Colonization with Aspergillus species was
present in six (18.2%) patients. Fifteen (45.5%) patients were
sensitized to A. fumigatus. Six patients were diagnosed as ABPA
by minimal diagnostic criteria giving prevalence of 18.2% (95% CI 6.9% -
35.4%). Out of six ABPA diagnosed patients, 3 were in acute stage, 2 in
exacerbation and 1 in remission [10].
Table I compares the clinical and
investigational profile of children diagnosed to be having ABPA with
those not having it. ABPA was more often seen in patients with low CF
score, age >12 years, reversibility after bronchodialator, atopy, and
eosinophilia. Patient with ABPA had a trend towards lower FEV1 and FVC.
Immediate skin reactivity to A. fumigatus was seen in 14
patients. Measures of correlation between IgE specific for A.
fumigatus and skin prick test showed no discordance. There was 87.5%
agreement between the two tests with a kappa value of 0.74. A similar
agreement (85.4%; kappa 0.68) was seen between total serum IgE level
(>500) and IgE specific for Aspergillus fumigatus (>3.5 KU). IgG
precipitins were negative in all patients.
TABLE I Comparison of Risk Factors Between ABPA and Non-ABPA Group
Variable |
ABPA (n=6) |
Non ABPA (n=27) |
P/ Odds ratio(CI) |
Age, mo
|
181.3 (71.2) |
133.0 (55.3) |
0.07 |
Males |
3 (50) |
21 (77) |
0.28 (0.04-1.73) |
*CF score
|
58.3 (10.8) |
75.2 (17.5) |
0.03 |
*Antibiotic use in last 1y
|
14.5 (5.5) |
15.6 (20.8) |
0.90 |
Reversibility on PFT |
3 (50) |
6 (31) |
3.5 (0.57-21.2) |
Pseudomonas present |
1 (16.7) |
12 (44.4) |
0.25 (0.01-2.79) |
Presence of AC |
1 (16.7) |
5 (18.5) |
0.88 (0.01-11.0) |
Inhaled antibiotics |
2 (33) |
8 (29.6) |
1.18 (0.08-10.39) |
Inhaled corticosteroids |
6 (100) |
26 (96) |
_ |
Azithromycin use |
5 (83) |
23 (85) |
0.86 |
AEC >500 |
4 (66) |
#4 (16)
|
10.5 (1.59-68.3) |
Atopy |
6 (100) |
$4 (15)
|
<0.001 |
Categorical values are mentioned as n (%); *Mean(SD);
#25 and $26
children. |
Discussion
Aspergillus species causing illness in children with
CF has a wide spectrum ranging from ABPA, colonization, IgE
sensitization and chronic bronchitis [7]. IgE sensitization of
aspergillus is associated with a more rapid decline of pulmonary
function [8]. Colonization of A. fumigatus is frequent with
reported prevalence of 40% but only 1% to 11% may develop ABPA [1].
Though there is increasing recognition of CF in India, there is paucity
of information about Aspergillus in children with CF [11]. We observed
prevalence of colonization and ABPA in 6 (18.2%) patients each in CF.
ABPA was more often seen in patients with low CF score, age >12 years,
airway reversibility, atopy, and high eosinophil count.
Various studies from Europe and United States have
reported prevalence of ABPA ranging from 2%-15% [12-14]. The high
prevalence of ABPA in our study may be due to low BMI, regular use of
azithromycin and ICS or frequent requirement of antibiotics for
pulmonary infections. Lower colonization rate (18%) with aspergillus in
present study could be because of stringent criteria of two sputum
samples collected on two consecutive days were positive instead of two
positive cultures over a period of one year used in other studies [8].
There was statistically significant correlation
between SPT and IgE specific A. fumigatus indicating that SPT can
be reliably done in screening for ABPA in resource limited countries.
In our study, none of the patients had positive test
for precipitins. Such negative results were seen in two previous studies
[7,14], which can be due to less potent antigens or poor IgG response.
Limitations of present study include: diagnosis of
bronchiectasis by X-ray rather than high resolution CT scans, and
use of IgG precipitins rather than IgG anti-Af ELISAs [15] Present study
provides data on different aspects of Aspergillus infection in children
with CF from India.
Acknowledgements: SRL diagnostics, India for
performing the assays for total and specific IgE.
Contributors: VK and DR: conceived and
designed the study, data collection and analysis; VK: drafted the
initial manuscript. DR, RL and SK: revision of manuscript and data
analysis. IX: microbiological and serological investigations; SK:
revised the manuscript for important intellectual content. He will act
as guarantor of the study. All authors approved the final manuscript.
Funding: None; Competing interest: None
stated.
What This Study Adds?
• Prevalence of
allergic bronchopulmonary aspergillosis in Indian children with
cystic fibrosis is 18%.
• ABPA is more common
in those with low CF score, age >12y, airway reversibility,
atopy, and eosinophilia.
|
References
1. Mroueh S, Spock A. Allergic bronchopulmonary
aspergillosis in patients with cystic fibrosis. Chest. 1994;105:32-6.
2. Ritz N, Ammann RA, Casaulta AC, Schoeni-Affolter
F, Schoeni MH. Risk factors for allergic bronchopulmonary aspergillosis
and sensitisation to Aspergillus fumigatus in patients with cystic
fibrosis. Eur J Pediatr. 2005;164: 577-82
3. Johansson SG. ImmunoCAP Specific IgE test: an
objective tool for research and routine allergy diagnosis. Expert Rev
Mol Diagn. 2004;4:273-9.
4. Faux JA, Shale DJ, Lane DJ. Precipitins and
specific IgG antibody to Aspergillus fumigatus in a chest unit
population. Thorax. 1992;47:48-52.
5. Simmonds EJ, Littlewood JM, Evans EG. Cystic
fibrosis and allergic bronchopulmonary aspergillosis Arch Dis Child.
1990;65:507–11.
6. Shwachman H, Kulczycki LL. Long-term study of one
hundred five patients with cystic fibrosis; studies made over a five- to
fourteen-year period. AMA J Dis Child. 1958;96:6-15.
7. Stevens DA, Moss RB, Kurup VP, Knutsen AP,
Greenberger P, Judson MA, et al. Allergic bronchopulmonary
aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis
Foundation Consensus Conference. Clin Infect Dis. 2003;37:S225-64.
8. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect
of chronic infection with Aspergillus fumigatus on lung function and
hospitalization in patients with cystic fibrosis. Chest. 2010;137:171-6.
9. Nepomuceno IB, Silvia E, Moss RB. Allergic broncho-pulmonary
aspergillosis in cystic fibrosis: Role of atopy and response to
itraconazole. Chest. 1999;115:364-70.
10. Greenberger PA, Patterson R. Diagnosis and
management of allergic bronchopulmonary aspergillosis. Ann Allergy.
1986;56:444-8.
11. Kabra SK, Kabra M, Lodha R, Shastri S. Cystic
fibrosis in India. Pediatr Pulmonol. 2007;42:1087-94.
12. Geller DE, Kaplowitz H, Light MJ, Colin AA.
Allergic bronchopulmonary aspergillosis in cystic fibrosis. Reported
prevalence, regional distribution and patient characteristic. Chest.
1999;116:639-46.
13. Mastella G, Rainisio M, Harms HK, Hodson ME, Koch
C, Navarro J, et al. Allergic bronchopulmonary aspergillosis in
cystic fibrosis. A European epidemiological study. Epidemiologic
Registry of Cystic Fibrosis. Eur Respir J. 2000;16:464-71.
14. Carneiro AC, Lemos AC, Arruda SM, Santana MA.
Prevalence of allergic bronchopulmonary aspergillosis in patients with
cystic fibrosis in the state of Bahia, Brazil. J Bras Pneumol.
2008;34:900-6.
15. Latzin P, Hartl D, Regamey N, Frey U, Schoeni MH,
Casaulta C. Comparison of serum markers for allergic bronchopulmonary
aspergillosis in cystic fibrosis. Eur Respir J. 2008;31:36-42.
|
|
|
|